89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4099-8
Abstract: BackgroundUp-to-date information on human epidermal growth factor receptor 2 (HER2) status in breast cancer (BC) is important, as expression can vary during the course of the disease, necessitating anti-HER2 therapy adjustments. Repeat biopsies, however, are… read more here.
Keywords: status; decision; her2 status; 89zr trastuzumab ... See more keywords
The expression of the insulin receptor in gastric cancer correlates with the HER2 status and may have putative therapeutic implications
Sign Up to like & getrecommendations! Published in 2019 at "Gastric Cancer"
DOI: 10.1007/s10120-019-00964-6
Abstract: BackgroundMetabolic reprogramming in gastric cancer (GC) involves not only an alteration of glucose metabolism, but also of insulin receptor (IR) expression. We investigated if (1) GCs express the IR in cancer cells (CC-IR) and vasculature… read more here.
Keywords: status; her2 status; gastric cancer; insulin receptor ... See more keywords
Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-020-06017-2
Abstract: Purpose The prognosis of patients with node-negative T1b tumors according to human epidermal growth factor receptor 2 (HER2) status is not known. This group of patients has not been studied in the available randomized trials.… read more here.
Keywords: cancer; her2 status; breast cancer;
Cognitive function and breast cancer molecular subtype before and after chemotherapy.
Sign Up to like & getrecommendations! Published in 2023 at "Applied neuropsychology. Adult"
DOI: 10.1080/23279095.2023.2176233
Abstract: Chemotherapy-related cognitive impairment has been reported in patients with breast cancer and received growing attention due to increased survival rate. However, cognitive outcome according to pathological tumor features, especially human epidermal growth factor receptor (HER2)… read more here.
Keywords: her2 status; breast cancer; chemotherapy;
HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqac179
Abstract: OBJECTIVES Human epidermal growth factor receptor 2 (HER2) status in endometrial cancer is usually determined by immunohistochemistry and/or in situ hybridization. We employed a novel HER2 gene protein assay (GPA) to simultaneously assesses HER2 gene… read more here.
Keywords: her2 status; her2 gene; her2; endometrial cancers ... See more keywords
510 Transitioning to an In-House In-Situ Hybridisation Assay Accelerates Indeterminate HER-2 Lesion Results
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Surgery"
DOI: 10.1093/bjs/znab259.209
Abstract: NICE guidelines 1.6.5 recommend that: ‘HER2 status [should be] available and recorded at the pre-operative multidisciplinary team (MDT) meeting when systemic treatment is discussed,’ to aid decision-making regarding neoadjuvant therapy. However, indeterminate HER2 lesions require… read more here.
Keywords: situ hybridisation; her2 status; time; decision making ... See more keywords
PO-506 The dynamics of HER2 status in esophageal adenocarcinoma
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.1007
Abstract: Introduction Trastuzumab, a monoclonal antibody against HER2, has become standard of care for metastatic HER2-overexpressing esophagogastric adenocarcinoma and is currently investigated as (neo)adjuvant treatment option in HER2-positive esophagogastric adenocarcinoma. The HER2 status is commonly determined… read more here.
Keywords: status; discordance; her2 status; treatment ... See more keywords
Abstract 3222: Assessment of change in HER2 status and its outcomes after neoadjuvant chemotherapy with trastuzumab and/or pertuzumab in early-stage breast cancer patients
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3222
Abstract: The use of neoadjuvant chemotherapy (NAC) has contributed to increased rates of disease-free survival (DFS) as well as overall survival in breast cancer patients, specifically those with HER2-positive disease. Pathological complete remission (pCR) in HER2-positive… read more here.
Keywords: her2 status; breast cancer; her2; status ... See more keywords
Abstract P5-08-12: HER2 status remains the primary predictor of improved survival in patients with BCBM over the past 2 decades (1996-2015)
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs16-p5-08-12
Abstract: BACKGROUND: Brain metastasis is a complication in advanced breast cancer (ABC) and is associated with poor prognosis. Incidence of breast cancer brain metastasis (BCBM) is increasing with advances in therapy, allowing patients to survive long… read more here.
Keywords: cancer; her2 status; bcbm; diagnosis ... See more keywords
Multicenter observational study on re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4038
Abstract: 4038Background: Addition of trastuzumab to cisplatin and fluoropyrimidine-based doublet chemotherapy is the standard first-line treatment for patients with human epidermal growth factor receptor 2 ... read more here.
Keywords: study evaluation; observational study; her2 status; trastuzumab ... See more keywords
Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.581
Abstract: 581Background: We have reported with the HERACLES Trial that HER2 amplification is a clinically relevant genetic alteration in metastatic colorectal cancer (mCRC). With present study, we aim to develop and internally validate a new diagnostic… read more here.
Keywords: metastatic colorectal; her2 status; colorectal cancer; clinicopathological characteristics ... See more keywords